Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

119 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Chemical targeting of the innate antiviral response by histone deacetylase inhibitors renders refractory cancers sensitive to viral oncolysis.
Nguyên TL, Abdelbary H, Arguello M, Breitbach C, Leveille S, Diallo JS, Yasmeen A, Bismar TA, Kirn D, Falls T, Snoulten VE, Vanderhyden BC, Werier J, Atkins H, Vähä-Koskela MJ, Stojdl DF, Bell JC, Hiscott J. Nguyên TL, et al. Among authors: diallo js. Proc Natl Acad Sci U S A. 2008 Sep 30;105(39):14981-6. doi: 10.1073/pnas.0803988105. Epub 2008 Sep 24. Proc Natl Acad Sci U S A. 2008. PMID: 18815361 Free PMC article.
Intelligent design: combination therapy with oncolytic viruses.
Ottolino-Perry K, Diallo JS, Lichty BD, Bell JC, McCart JA. Ottolino-Perry K, et al. Among authors: diallo js. Mol Ther. 2010 Feb;18(2):251-63. doi: 10.1038/mt.2009.283. Epub 2009 Dec 22. Mol Ther. 2010. PMID: 20029399 Free PMC article. Review.
Synergistic interaction between oncolytic viruses augments tumor killing.
Le Boeuf F, Diallo JS, McCart JA, Thorne S, Falls T, Stanford M, Kanji F, Auer R, Brown CW, Lichty BD, Parato K, Atkins H, Kirn D, Bell JC. Le Boeuf F, et al. Among authors: diallo js. Mol Ther. 2010 May;18(5):888-95. doi: 10.1038/mt.2010.44. Epub 2010 Mar 16. Mol Ther. 2010. PMID: 20234341 Free PMC article.
A high-throughput pharmacoviral approach identifies novel oncolytic virus sensitizers.
Diallo JS, Le Boeuf F, Lai F, Cox J, Vaha-Koskela M, Abdelbary H, MacTavish H, Waite K, Falls T, Wang J, Brown R, Blanchard JE, Brown ED, Kirn DH, Hiscott J, Atkins H, Lichty BD, Bell JC. Diallo JS, et al. Mol Ther. 2010 Jun;18(6):1123-9. doi: 10.1038/mt.2010.67. Epub 2010 Apr 13. Mol Ther. 2010. PMID: 20389287 Free PMC article.
Enhancement of vaccinia virus based oncolysis with histone deacetylase inhibitors.
MacTavish H, Diallo JS, Huang B, Stanford M, Le Boeuf F, De Silva N, Cox J, Simmons JG, Guimond T, Falls T, McCart JA, Atkins H, Breitbach C, Kirn D, Thorne S, Bell JC. MacTavish H, et al. Among authors: diallo js. PLoS One. 2010 Dec 30;5(12):e14462. doi: 10.1371/journal.pone.0014462. PLoS One. 2010. PMID: 21283510 Free PMC article.
A mechanistic proof-of-concept clinical trial with JX-594, a targeted multi-mechanistic oncolytic poxvirus, in patients with metastatic melanoma.
Hwang TH, Moon A, Burke J, Ribas A, Stephenson J, Breitbach CJ, Daneshmand M, De Silva N, Parato K, Diallo JS, Lee YS, Liu TC, Bell JC, Kirn DH. Hwang TH, et al. Among authors: diallo js. Mol Ther. 2011 Oct;19(10):1913-22. doi: 10.1038/mt.2011.132. Epub 2011 Jul 19. Mol Ther. 2011. PMID: 21772252 Free PMC article. Clinical Trial.
The oncolytic poxvirus JX-594 selectively replicates in and destroys cancer cells driven by genetic pathways commonly activated in cancers.
Parato KA, Breitbach CJ, Le Boeuf F, Wang J, Storbeck C, Ilkow C, Diallo JS, Falls T, Burns J, Garcia V, Kanji F, Evgin L, Hu K, Paradis F, Knowles S, Hwang TH, Vanderhyden BC, Auer R, Kirn DH, Bell JC. Parato KA, et al. Among authors: diallo js. Mol Ther. 2012 Apr;20(4):749-58. doi: 10.1038/mt.2011.276. Epub 2011 Dec 20. Mol Ther. 2012. PMID: 22186794 Free PMC article.
119 results